Liver-directed lentiviral gene therapy in a dog model of hemophilia B
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Gene therapy with lentiviral vectors targeting transgene expression to hepatocytes provides stable reconstitution of clotting activity in dogs with hemophilia B and does not show genotoxicity in tumor-prone mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [79]
Experimental — accuracy not yet measuredIn the citing paper
“Although AAV efforts predominate, lentiviral vectors for either systemic infusion157,158 or ex vivo transduction of hematopoietic stem cells159, 160, 161 or induced pluripotent stem cells162 are being pursued preclinically or as a phase I clinical trial.156”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Self-citationHepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model
Weber, L. W. D., Boll, M., & Stampfl, A. (2003) · Critical Reviews in Toxicology · doi:10.1080/713611034 · Cited by 1,777 · cited 1×
“CCl4 administration results in waves of hepatocytes necrosis and regeneration that cause liver damage (41).”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationHowe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180 · cited 5×
“We produced three large-scale batches of lentiviral vectors according to a manufacturing process previously developed for clinical-grade lentiviral vectors (19, 20).”
BackgroundMethodSelf-citationOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Self-citationLentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025 · cited 4×
“The vector batches were produced by using a large-scale validated process (19, 20) and following pre-GMP guidelines.”
BackgroundMethodSelf-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“However, there are still important hurdles to overcome before this gene therapy can be applied to the majority of severely affected patients (9).”
Background
Cited by
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Self-citationClinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
“A phase 1/2 study of a non-primate lentiviral vector based upon the equine infectious anemia virus (EIAV) expressing three genes involved in dopamine metabolism demonstrated the safety of local lentiviral gene delivery into the central nervous system with some evidence of clinical benefit [79].”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing
Amabile, A., Migliara, A., Capasso, P., Biffi, M., Cittaro, D., Naldini, L., & Lombardo, A. (2016) · Cell · doi:10.1016/j.cell.2016.09.006 · Cited by 516
“VSG-G pseudotyped LV stocks were prepared as previously described Cell 167, 219–232.e1–e6, September 22, 2016 e3 (Cantore et al., 2015).”
MethodSelf-citationRole of animal models in biomedical research: a review
Mukherjee, P., Roy, S., Ghosh, D., & Nandi, S. K. (2022) · Laboratory Animal Research · doi:10.1186/s42826-022-00128-1 · Cited by 502
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming
Bénéchet, A. P., De Simone, G., Di Lucia, P., Cilenti, F., Barbiera, G., Le Bert, N., Fumagalli, V., Lusito, E., Moalli, F., Bianchessi, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1620-6 · Cited by 222
Self-citationViral Vectors in Gene Therapy: Where Do We Stand in 2023?
Lundstrom, K. (2023) · Viruses · doi:10.3390/v15030698 · Cited by 187
Labbé, R. P., Vessillier, S., & Rafiq, Q. A. (2021) · Viruses · doi:10.3390/v13081528 · Cited by 177
“LV vectors have been used in multiple pre-clinical applications for the treatment of hereditary diseases such as haemophilia B [12] and macular degeneration [13] by in vivo delivery.”
MethodPhagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates
Milani, M., Annoni, A., Moalli, F., Liu, T., Cesana, D., Calabria, A., Bartolaccini, S., Biffi, M., Russo, F., Visigalli, I., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7325 · Cited by 142
Self-citationNovel vectors and approaches for gene therapy in liver diseases
Maestro, S., Weber, N. D., Zabaleta, N., Aldabe, R., & González‐Aseguinolaza, G. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100300 · Cited by 159
“liver expression of factor IX, induction of tolerance against the recombinant protein and no evidence of genotoxicity.(134) However, mild acute toxicity and low efficacy were observed due to collateral transduction of resident antigen-presenting cells (APCs) in the liver (Kupffer cells and hepatic stellate cells).”
BackgroundMichels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 144
Novel approaches to hemophilia therapy: successes and challenges
Arruda, V. R., Doshi, B. S., & Samelson‐Jones, B. J. (2017) · Blood · doi:10.1182/blood-2017-08-742312 · Cited by 124
Advances and innovations in haemophilia treatment
Peters, R., & Harris, T. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.70 · Cited by 122
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“…development: i) systemic lentiviral-mediated liver-restricted gene therapy in a dog model of haemophilia B, which showed long-term efficacy, induction of liver tolerogenic properties in stimulating CD4+CD25+FoxP3+ regulatory T cells and no evidence of genotoxicity in mice (Cantore et al 2015).”
BackgroundDesigning Lentiviral Vectors for Gene Therapy of Genetic Diseases
Poletti, V., & Mavilio, F. (2021) · Viruses · doi:10.3390/v13081526 · Cited by 120
“Additionally, in a liver hepatocyte context, integration site analysis carried out in hemophilia B mice showed no evidence of clonal dominance, while the overall safety profile of the vector was demonstrated in two mouse models with enhanced sensitivity to hepatocellular carcinogenesis [68].”
BackgroundGene therapy for hemophilia: what does the future hold?
Doshi, B. S., & Arruda, V. R. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718791933 · Cited by 97
A Molecular Revolution in the Treatment of Hemophilia
Butterfield, J. S. S., Hege, K. M., Herzog, R. W., & Kaczmarek, R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.006 · Cited by 94
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Self-citationGene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1
Hickey, R. D., Mao, S. A., Glorioso, J., Elgilani, F., Amiot, B., Chen, H., Rinaldo, P., Marler, R., Jiang, H., DeGrado, T. R., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf3838 · Cited by 75
Adeno-associated viral vectors for the treatment of hemophilia
High, K. A., & Anguela, X. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv475 · Cited by 73
Milani, M., Annoni, A., Bartolaccini, S., Biffi, M., Russo, F., Di Tomaso, T., Raimondi, A., Lengler, J., Holmes, M. C., Scheiflinger, F., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708148 · Cited by 72
“…independent targeted integrations (T.I.) of LV constructs expressing GFP or human FIX, either wild-type (wt) or a codon-optimized hyper-functional version (FIX-Padua; Fig EV1A; Cantore et al, 2015), by transiently co-delivering zinc-finger nucleases (ZFN) targeting AAVS1 and the plasmid donor DNA.”
BackgroundMethodSelf-citationGene therapy for immune tolerance induction in hemophilia with inhibitors
Arruda, V. R., & Samelson‐Jones, B. J. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13331 · Cited by 69
Scrudato, M. L., Poulard, K., Sourd, C., Tomé, S., Klein, A. F., Corre, G., Huguet-Lachon, A., Furling, D., Gourdon, G., & Buj‐Bello, A. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.021 · Cited by 70
A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice
Merlin, S., Cannizzo, E. S., Borroni, E., Bruscaggin, V., Schinco, P., Tulalamba, W., Chuah, M. K., Arruda, V. R., VandenDriessche, T., Prat, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.029 · Cited by 59
Self-citationProtein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Pseudotyping Lentiviral Vectors: When the Clothes Make the Virus
Duvergé, A., & Negroni, M. (2020) · Viruses · doi:10.3390/v12111311 · Cited by 70
Olgasi, C., Talmon, M., Merlin, S., Cucci, A., Richaud‐Patín, Y., Ranaldo, G., Colangelo, D., Scipio, F. D., Berta, G. N., Borsotti, C., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.10.012 · Cited by 59
“Several approaches for hemophilia gene therapy using lentiviral vectors (LVs) were developed and tested in preclinical models showing promising results (Cantore et al., 2015; Merlin et al., 2017).”
BackgroundCorrection of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
Lattanzi, A., Duguez, S., Moiani, A., Izmiryan, A., Barbon, E., Martin, S., Mamchaoui, K., Mouly, V., Bernardi, F., Mavilio, F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.004 · Cited by 72
Self-citationImpact of novel hemophilia therapies around the world
Ozelo, M. C., & Yamaguti-Hayakawa, G. G. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12695 · Cited by 63
Schaeffer, C., Merella, S., Pasqualetto, E., Lazarević, D., & Rampoldi, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175970 · Cited by 53
Milani, M., Canepari, C., Liu, T., Biffi, M., Russo, F., Plati, T., Curto, R., Patarroyo-White, S. L., Drager, D., Visigalli, I., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30102-3 · Cited by 61
Self-citationMeneghini, V., Lattanzi, A., Tiradani, L., Bravo, G., Morena, F., Sanvito, F., Calabria, A., Bringas, J., Fisher‐Perkins, J. M., Dufour, J., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505850 · Cited by 54
Self-citationGene Therapy Developments for Pompe Disease
Unnisa, Z., Yoon, J. K., Schindler, J. W., Mason, C., & van Til, N. P. (2022) · Biomedicines · doi:10.3390/biomedicines10020302 · Cited by 60
Hemophilia Gene Therapy: The End of the Beginning?
Wolf, D. D., Singh, K., Chuah, M., & VandenDriessche, T. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.112 · Cited by 50
“80 Ideally, efficient targeted integration would be preferred based on the integration of the FVIII or FIX trans-genes into a so-called ‘safe harbor’ locus in the genome or by editing the defective endogenous FVIII or FIX genes themselves.”
Self-citationPierce, G. F., & Iorio, A. (2018) · Haemophilia · doi:10.1111/hae.13489 · Cited by 47
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
Samelson-Jones, B. J., Finn, J. D., George, L. A., Camire, R. M., & Arruda, V. R. (2019) · JCI Insight · doi:10.1172/jci.insight.128683 · Cited by 44
Retrieval of vector integration sites from cell-free DNA
Cesana, D., Calabria, A., Rudilosso, L., Gallina, P., Benedicenti, F., Spinozzi, G., Schiroli, G., Magnani, A., Acquati, S., Fumagalli, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01389-4 · Cited by 44
Self-citationLiver‐directed gene therapy for inherited metabolic diseases
Baruteau, J., Brunetti‐Pierri, N., & Gissen, P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12709 · Cited by 48
“10 Moreover, the efficient genomic integration of LV vectors gives them an advantage over AAV vectors when targeting growing livers.”
BackgroundEfficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector
Coradin, T., Keating, A. L., Barnard, A. R., Whilding, L. M., Pombal, D., Hannoun, Z., Lewis, J., Devarajan, G., Iqball, S., Burton, E., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.006 · Cited by 44
“26 We therefore further evaluated the specificity of the retargeted vectors by analyzing integrated vector copy number (VCN) in the liver of treated animals.”
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Lessons learned from lung and liver in-vivo gene therapy: implications for the future
van Haasteren, J., Hyde, S. C., & Gill, D. R. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1506761 · Cited by 47
Samelson‐Jones, B. J., & Arruda, V. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00618 · Cited by 43
“No evidence of an anti-cFIX immune response has been reported after AAV (59, 62–65) or LV (66) liver-directed gene transfer with cFIX in 11 and 3 non-inhibitor-prone HB dogs, respectively, though only 1 dog has been subsequently challenged with canine plasma for bleeding (64).”
BackgroundWolff, J. H., & Mikkelsen, J. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00865-4 · Cited by 47
“Using the miR-142-3p-regulated vector configuration, stable reconstitution of Factor IX (up to 1% of normal) was achieved in three hemophilia dogs leading to a reduction of spontaneous bleeding events in all three animals treated with in vivo lentiviral gene therapy [113].”
BackgroundMethodContemporary Animal Models For Human Gene Therapy Applications
Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D., & Nelson, E. J. R. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150929110424 · Cited by 49
“In a few recent gene therapy studies, dogs have also been used as models for haemophilia [63, 64], ocular disorders [65, 66] and cardiovascular diseases [67, 68].”
BackgroundNichols, T. C., Hough, C. A., Agersø, H., Ezban, M., & Lillicrap, D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13301 · Cited by 45
Self-citationEmerging gene therapies for cystic fibrosis
Miah, K. M., Hyde, S. C., & Gill, D. R. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1634547 · Cited by 48
“Lentiviral vectors pseudotyped with the canonical VSV-G protein from Vesicular stomatitis virus have broad tissue specificity (including the eyes/retina [104], the CNS [105], and the liver [106,107]).”
BackgroundUncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives
Chernyi, N., Gavrilova, D., Saruhanyan, M., Oloruntimehin, E. S., Karabelsky, A. V., Bezsonov, E. E., & Malogolovkin, A. S. (2024) · Biomolecules · doi:10.3390/biom14070854 · Cited by 48
“To produce long-term steady production of FIX in dogs with hemophilia B, a self-inactivating LV vector (SIN-LV), including a hepatocyte-specific promoter, was employed [104].”
McDonald, M. F., Hossain, A., Momin, E. N., Hasan, I., Singh, S. K., Adachi, S., Gumin, J., Ledbetter, D., Yang, J., Long, L., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad199 · Cited by 40
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis
Caputo, S., Grioni, M., Brambillasca, C. S., Monno, A., Brevi, A., Freschi, M., Piras, I. S., Elia, A. R., Pieri, V., Baccega, T., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01820 · Cited by 41
Self-citationMoshref, M., Tangey, B., Gilor, C., Papas, K. K., Williamson, P., Loomba‐Albrecht, L. A., Sheehy, P. A., & Kol, A. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0163 · Cited by 50
Kachanov, A., Kostyusheva, A. P., Brezgin, S. A., Karandashov, I. V., Ponomareva, N. I., Tikhonov, A., Lukashev, A. N., Pokrovsky, V. S., Zamyatnin, A. A., Parodi, A., et al. (2024) · Medicinal Research Reviews · doi:10.1002/med.22036 · Cited by 49
Munis, A. M., Mattiuzzo, G., Bentley, E. M., Collins, M. K., Eyles, J. E., & Takeuchi, Y. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.010 · Cited by 39
Genetic-Based Approaches to Inherited Metabolic Liver Diseases
Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 36
“72 Strategies to avoid uptake by phagocytic cells are at present under investigation to improve hepatocyte transduction and to reduce systemic toxicity.”
Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level
Kang, D. D., Marks, A. R., Morlà‐Folch, J., Dong, Y., Brown, B. D., & Teunissen, A. J. P. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01511-8 · Cited by 51
“Subsequent work by numerous laboratories has shown that miRTs can suppress vector expression in many cell types 147,150–152 , including hepatocytes with miR-122T 147,153–155 , HSCs and endothelial cells with miR-126T 147,156 , neurons with miR-124T 157–161 , myocytes with miR-206T 162 , and B and T…”
Obstacles and future of gene therapy for hemophilia
Arruda, V. R., & Samelson-Jones, B. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1069179 · Cited by 33
“5 years for two animals that received a codonoptimized FIX wild type or FIX Padua; moreover, in provocative mice models for oncogenesis, no genotoxicity was observed with this lentiviral approach [63].”
BackgroundInnovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
An Optimized Lentiviral Vector Efficiently Corrects the Human Sickle Cell Disease Phenotype
Weber, L., Poletti, V., Magrin, E., Antoniani, C., Martin, S., Bayard, C., Sadek, H., Félix, T., Meneghini, V., Antoniou, M. N., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.012 · Cited by 34
Self-citationTherapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes
Vonada, A., Tiyaboonchai, A., Nygaard, S. C., Posey, J., Peters, A. M., Winn, S. R., Cantore, A., Naldini, L., Harding, C. O., & Grompe, M. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg3047 · Cited by 31
Self-citationCellular Proteo-Transcriptomic Changes in the Immediate Early-Phase of Lentiviral Transduction
Linkner, T. R., Ambrus, V., Kunkli, B., Szojka, Z. I., Kalló, G., Csősz, É., Kumar, A., Emri, M., Tőzsér, J., & Mahdi, M. (2021) · Microorganisms · doi:10.3390/microorganisms9112207 · Cited by 33
“Additionally, direct in vivo delivery of genes carried by equine infectious anemia virus (EIAV)-based vectors into target tissues has been utilized successfully in a dog model of hemophilia B and patients with advanced neovascular age-related macular degeneration (NVAMD) with evidence of therapeutic potential and a pr…”
BackgroundChen, J., An, B., Yu, B., Peng, X., Yuan, H., Yang, Q., Chen, X., Yu, T., Wang, L., Zhang, X., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.224063 · Cited by 32
Delivering on the promise of gene therapy for haemophilia
Pipe, S. W. (2020) · Haemophilia · doi:10.1111/hae.14027 · Cited by 32
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Self-citationGene therapy for hemophilia: Progress to date and challenges moving forward
Gollomp, K. L., Doshi, B. S., & Arruda, V. R. (2019) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2019.08.012 · Cited by 33
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
Cantore, A., & Naldini, L. (2020) · Haemophilia · doi:10.1111/hae.14056 · Cited by 33
Self-citationGene therapy for urea cycle defects: An update from historical perspectives to future prospects
Duff, C. E., Alexander, I. E., & Baruteau, J. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12609 · Cited by 32
“80,81”
Nicolas, C. T., VanLith, C. J., Hickey, R., Du, Z., Hillin, L. G., Guthman, R. M., Cao, W. J., Haugo, B. J., Lillegard, A., Roy, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32576-7 · Cited by 37
Lentiviral vector interactions with the host cell
Borsotti, C., Borroni, E., & Follenzi, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.016 · Cited by 30
Estève, J., Blouin, J., Lalanne, M., Martin, L. A., Dubus, P. R., Bidet, A., Harambat, J., Llanas, B., Moranvillier, I., Bedel, A., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101467 · Cited by 29
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Gene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
Merlin, S., & Follenzi, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.013 · Cited by 25
Ornaghi, F., Sala, D., Tedeschi, F., Maffia, M. C., Bazzucchi, M., Morena, F., Valsecchi, M., Aureli, M., Martino, S., & Gritti, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104667 · Cited by 31
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
“In vivo approaches in hemophilia have involved delivery of liver-directed and integration-deficient lentivirus vectors in hemophilia animal models, resulting in correction of bleeding and sustained activity [27, 28].”
BackgroundIn-Vivo Gene Therapy with Foamy Virus Vectors
Rajawat, Y. S., Humbert, O., & Kiem, H. (2019) · Viruses · doi:10.3390/v11121091 · Cited by 27
Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy
VandenDriessche, T., & Chuah, M. K. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.007 · Cited by 24
Self-citationCarbonaro-Sarracino, D. A., Tarantal, A. F., Lee, C. C. I., Kaufman, M. L., Wandro, S., Jin, X., Martinez, M. L., Clark, D. N., Chun, K. M., Koziol, C., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.004 · Cited by 24
Gene Therapy for Coagulation Disorders
Swystun, L. L., & Lillicrap, D. (2016) · Circulation Research · doi:10.1161/circresaha.115.307015 · Cited by 26
Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis
Cottone, L., Capobianco, A., Gualteroni, C., Monno, A., Raccagni, I., Valtorta, S., Canu, T., Tomaso, T. D., Lombardo, A., Esposito, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1122860 · Cited by 23
“VSV-G pseudotyped third generation lentiviral vectors expressing the amiRs were produced by transient four plasmid cotransfection into HEK293T cells and concentrated by ultracentrifugation.(38)”
MethodSelf-citationHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Self-citationAdvances in Delivery Vectors for Gene Therapy in Liver Cancer
Bowman, K. E. R., Lu, P., Mause, E. R. V., & Lim, C. S. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0076 · Cited by 24
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 25
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Monahan, P. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.33 · Cited by 24
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice
Milani, M., Canepari, C., Assanelli, S., Merlin, S., Borroni, E., Starinieri, F., Biffi, M., Russo, F., Fabiano, A., Zambroni, D., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00072-8 · Cited by 19
“…systemic administration of lentiviral vectors (LV) showed stable liver gene transfer in animal models, such as mice, dogs, and non-human primates (NHP), and allowed phenotypic correction of hemophilia models (Cantore et al, 2015; Merlin et al, 2017; Milani et al, 2019, 2022; Nicolas et al, 2022).”
Self-citationIn vivo liver targeted genome editing as therapeutic approach: progresses and challenges
Simoni, C., Barbon, E., Muro, A. F., & Cantore, A. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1458037 · Cited by 23
Self-citationStaber, J. M. R., Pollpeter, M. J., Anderson, C.-G., Burrascano, M., Cooney, A. L., Sinn, P. L., Rutkowski, D. T., Raschke, W. C., & McCray, P. B. (2017) · Gene Therapy · doi:10.1038/gt.2017.67 · Cited by 18
Emerging Therapeutic Approaches for Diamond Blackfan Anemia
Aspesi, A., Borsotti, C., & Follenzi, A. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181109124538 · Cited by 23
Enhancing the potency of in vivo lentiviral vector mediated gene therapy to hepatocytes
Canepari, C., Milani, M., Simoni, C., Starinieri, F., Volpin, M., Fabiano, A., Biffi, M., Russo, F., Norata, R., Rocchi, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60073-0 · Cited by 19
“We and others previously showed stable LV-mediated liver gene transfer in both small and large animal models, resulting in the correction of hemophilia and other inherited liver diseases 5 – 9 .”
Self-citationLiver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
Gene therapies targeting the liver
Cozmescu, A. C., Counsell, J. R., & Gissen, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.003 · Cited by 17
Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors
Arrasate, A., Lopez-Robles, C., Zuazo, M., Baños-Mateos, S., Martín, C., Lamsfus‐Calle, A., & Fertin, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178497 · Cited by 15
“Regarding in vivo approaches, when the natural biodistribution that follows the systemic administration of vectors is favorable, such as in liver-targeting therapies, LVVs pseudotyped with the VSV-G have proved to be successful [113,114].”
Çelik, B., Rintz, E., Sansanwal, N., Khan, S. A., Bigger, B., & Tomatsu, S. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.094 · Cited by 17
Thompson, W. S., Mondal, G., VanLith, C. J., Kaiser, R. A., & Lillegard, J. B. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1791082 · Cited by 15
Perspective on innovative therapies for globoid cell leukodystrophy
Ricca, A., & Gritti, A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23752 · Cited by 16
“, 2014) and systemic (Cantore et al., 2015) delivery, and transduce mammalian neuronal and glial cells with high efficiency (Hendriks et al.”
BackgroundClinical perspective: Advancing hemophilia treatment through gene therapy approaches
Thornburg, C. D., PIPE, S. W., Cantore, A., Unzu, C., Jones, M., & Miesbach, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.023 · Cited by 13
Self-citation
Metadata
- Authors
- Cantore, A., Ranzani, M., Bartholomae, C. C., Volpin, M., Valle, P. D., Sanvito, F., Sergi, L. S., Gallina, P., Benedicenti, F., Bellinger, D., Raymer, R., Merricks, E., Bellintani, F., Martin, S., Doglioni, C., D’Angelo, A., VandenDriessche, T., Chuah, M. K., Schmidt, M., Nichols, T., Montini, E., & Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- German Cancer Research Center (DE)
- IRCCS Ospedale San Raffaele (IT)
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- University of North Carolina at Chapel Hill (US)
- MolMed (Italy) (IT)
- Genethon (France) (FR)
- Université Libre de Bruxelles (BE)
- Corresponding author
- Cantore, Alessio
- Ranzani, Marco
- Nichols, Timothy
- Montini, Eugenio
- Naldini, Luigi
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-03-04
- Volume
- 7
- Issue
- 277
- Pages
- 277ra28-277ra28
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5669486
- OpenAlex
- W2099852853
- Cited by
- 158
- References
- 52
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 12 · 2023: 15 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 19 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 7
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- HAL (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- NIH (HL063098)
- European Union Seventh Framework Programme (222878-PERSIST)
- European Research Council Advanced
- Telethon (D3)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, lentiviral vectors, liver-directed gene therapy, canine model, insertional mutagenesis, genotoxicity, hepatocytes, coagulation factor IX, large animal model
- MeSH terms
- Animals, Blood Coagulation, Hemophilia B, Disease Models, Animal, Dogs, Female, Genetic Vectors, Liver, Mice, Inbred C57BL, Mutagens, Time Factors, Transduction, Genetic, Genetic Therapy, Lentivirus, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.